Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Impact · against what's priced in

The article provides no new catalysts for Alnylam, as its current profitability and cash position are already reflected in the stock price. The narrative reinforces that the market is ignoring strong current financials in favor of growth concerns already priced in.

ALNY+0.00

Already priced in

The price assumes

Current GAAP profitability and a $3.0 billion cash position

The reported GAAP net income of $164.5 million and $3.3 billion cash balance simply confirm the profitability and liquidity the market has already accounted for.